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Human bocavirus 1 (HBoV1) DNA is frequently detected 
in the upper airways of young children with respiratory 
symptoms. Because of its persistence and frequent co-
detection with other viruses, however, its etiologic role 
has remained controversial. During 2009–2011, using 
HBoV1 IgM, IgG, and IgG-avidity enzyme immunoassays 
and quantitative PCR, we examined 1,952 serum samples 
collected consecutively at 3- to 6-month intervals from 
109 constitutionally healthy children from infancy to early 
adolescence. Primary HBoV1 infection, as indicated by 
seroconversion, appeared in 102 (94%) of 109 children at 
a mean age of 2.3 years; the remaining 7 children were 
IgG antibody positive from birth. Subsequent secondary 
infections or IgG antibody increases were evident in 38 
children and IgG reversions in 10. Comparison of the 
seroconversion interval with the next sampling interval 
for clinical events indicated that HBoV1 primary infection, 
but not secondary immune response, was signiﬁ  cantly 
associated with acute otitis media and respiratory illness.
H
uman bocavirus 1 (HBoV1), a new member of 
the  Bocavirus genus of the family Parvoviridae, 
was discovered in 2005 by large-scale sequencing in 
nasopharyngeal samples from children (1). HBoV1 DNA 
has since been frequently detected by PCR in the upper 
airways of young children who have upper or lower 
respiratory tract illness (URTI, LRTI) and, less frequently, 
in their feces (2,3). Furthermore, 3 other bocaviruses, 
HBoV2, 3, and 4, were recently detected in human 
feces (4–6), and HBoV2 has been associated with acute 
gastroenteritis (5).
HBoV1 in the upper airways also occurs persistently 
or recurrently in asymptomatic children (7–11). Because 
of these characteristics and frequent co-detection with 
other viruses, the role of HBoV1 in respiratory illness has 
been questioned. Circumventing the PCR-related problems 
of prolonged or recurrent positivity and disclosing the 
association of HBoV1 infection with disease require a more 
reliable diagnosis that uses serum for PCR and antibody 
detection (12–16). By using serology, one can distinguish 
between primary and secondary HBoV1 infections. We 
recently detected secondary HBoV1 immunoactivations 
in immunocompetent adults (17), but no data exist on the 
clinical effects of such events or on their frequency in 
children. Furthermore, to our knowledge, no prospective 
studies with reliable diagnostics have been conducted 
to determine the clinical associations of primary HBoV1 
infection.
We determined HBoV1 primary infection in relation 
to clinical symptoms among constitutionally healthy 
children who were serologically followed from infancy up 
to age 13 years. In addition, we investigated the kinetics of 
HBoV1 viremia and IgG and IgM antibody responses, IgG 
avidity maturation, and the occurrence and clinical effects 
of secondary infections or immunoactivations.
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Materials and Methods
Patients and Samples
We conducted this study during 2009–2011. 
Participants were from the ongoing population-based 
Diabetes Prediction and Prevention (DIPP) study, a 
prospective survey of the preclinical events preceding 
type 1 diabetes among genetically susceptible children 
in Finland (18,19). These children, who carry speciﬁ  c 
human leukocyte antigen (HLA)–DQ genotypes conferring 
increased susceptibility to type 1 diabetes, were observed 
from birth for the appearance of diabetes-associated 
antibodies and viral infections. By the end of 2002, a total 
of 68,953 newborn children (27,030 in Turku) had been 
tested for their HLA-conferred risk for type 1 diabetes. 
From this group, 10,743 (4,391 in Turku) were invited to 
join the DIPP study, and 8,014 (2,942) of these participated.
The 109 DIPP children in this study were randomly 
chosen (computer algorithm that gives equal relative 
amounts of all HLA types studied) from children born 
during 1995–2002 in Turku, fulﬁ  lling the following criteria: 
1) to ensure that all their samples were not contaminated 
or otherwise compromised (e.g., multiple thaws), these 
children’s samples had never been used in any previous 
studies; 2) participating children had been followed up 
according to the sampling schedule as promptly as possible; 
and 3) the children had to be of normal health and did not 
have type 1 diabetes or any diabetes-related antibodies 
by the end of 2002. Of these 109 constitutionally healthy 
children, 56 were girls. We analyzed the children’s 1,952 
serum samples (mean of 18 samples per child, median 17, 
range 12–27), obtained from the average age of 3 months 
(median 0.31 years, range 0.20–0.91 years) to an average 
of 8 years (median 8.5 years, range 4–13 years), as well 
as umbilical cord blood samples from 9 selected children. 
The 109 children were examined at a mean interval of 110 
days (median 96 days, range 55–484 days) until age 2 years 
and subsequently at a mean interval of 197 days (median 
182 days, range 92–849 days) until October 2008 (unless 
they were discontinued earlier). At each examination, a 
serum sample was drawn, divided into aliquots, and stored 
at –70°C. All serum samples were tested for IgG and IgM 
antibodies against HBoV1. HBoV1 IgG avidity and HBoV1 
quantitative PCR (qPCR) were conducted on the 3 specimens 
ﬂ  anking each serodiagnosis (primary and secondary IgG 
antibody increases). At each child’s scheduled visit, the 
parents completed a questionnaire and were interviewed by 
a study nurse about any clinical symptoms or illnesses since 
the previous visit. Acute otitis media (AOM), sinusitis, 
tonsillitis and LRTI were diagnosed by a physician. All 
prescribed antimicrobial drugs were also recorded. Thirty 
(28%) children had physician-diagnosed allergic diseases, 
e.g., asthma; diabetes-associated autoantibodies developed 
in 7 (6%) children, but none of these children progressed to 
clinical diabetes.
The ethics committee of the Hospital District of 
Southwest Finland approved the study protocol. The 
legal guardians of the study participants provided written 
informed consent.
Enzyme Immunoassays
HBoV1 IgG and μ-capture IgM enzyme immunoassays 
(EIAs) were conducted as described (13) with biotinylated 
virus–like viral protein 2 particles as the antigen. The 
diagnostic sensitivity was 97% and speciﬁ  city  99.5% 
for these EIAs done in combination (13). Our diagnostic 
criteria for HBoV1 primary infection were seroconversion 
or PCR positivity in serum occurring for the ﬁ  rst time; and 
for an HBoV1 secondary immunoactivation, a >4-fold titer 
increase in IgG antibodies in 2 adjacent serum samples 
after seropositivity. We used a protein-denaturing EIA to 
analyze HBoV1 IgG avidity (17). All samples from each 
child were studied in parallel.
Real-time qPCR
The DNA in 20 μL of serum was extracted by phenol-
chloroform, precipitated by sodium acetate and ethanol, 
and then eluted in 20 μL of 10 mmol/L Tris-Cl buffer 
(pH 8.0); 5 μL was assayed by using PCR. The HBoV1 
nucleoprotein 1 (NP1) gene-based qPCR was performed as 
described (12,20) with a Stratagene Mx3005P instrument 
(Agilent Technologies, Santa Clara, CA, USA). The 
quantiﬁ   cation standard was a plasmid (pSt2; GenBank 
accession no. DQ000496) containing the HBoV1 NP1 gene 
comprising serial dilutions covering 7 logs. Water served 
as negative controls and pSt2 as the positive control. The 
3 serum samples from each child, including and ﬂ  anking 
the seroconversion or secondary increase(s), were studied 
in parallel.
Statistics of Clinical Correlates
Any infection-related illnesses—URTI (with fever or 
>2 respiratory symptoms), LRTI, fever without respiratory 
tract infection, tonsillitis, AOM, conjunctivitis, sinusitis, 
gastroenteritis (with vomiting or diarrhea), exanthema with 
fever, and other infection-related illnesses—during the 
HBoV1 primary infection or during the secondary immune 
response were compared with illnesses during the previous 
sample interval and the subsequent interval in each child. 
One child, for whom complete clinical information 
was lacking, was excluded. Liddell exact test served for 
statistical analyses, and p values <0.05 were considered 
signiﬁ  cant.
Additionally, we compared the stability of or decrease 
in IgG antibodies after conversion in each child during the 
entire study, with the presence of allergic diseases, diabetes-
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associated antibodies, symptoms at HBoV1 primary 
infection, and with the child’s increased susceptibility to 
infections in general, as deﬁ  ned by the pediatric infectious 
disease specialists of Turku University Hospital on the basis 
of clinical features in primary immunodeﬁ  ciency diseases 
(21), by the number of infection episodes (>10 AOM, >2 
acute sinusitis, >1 pneumonia or >1 acute pyelonephritis), 
tonsillectomy or insertion of tympanostomy tubes because 
of recurrent infections. We used the Fisher exact test and 




A total of 1,961 consecutive serum samples from 109 
constitutionally healthy children, including the 9 cord blood 
samples, were studied for HBoV1 IgG and IgM antibodies. 
All 109 children were seropositive for HBoV1 by age 6 
years (Figure 1). Seven children remained seropositive 
from birth, and 102 children showed seroconversion at the 
mean age of 2.3 years (median 2.1, range 0.3–6.0) (Tables 
1–3). Ages did not change substantially when calculated 
according to the mid-point of the seroconversion interval 
(mean 2.1 years, median 1.9 years, range 0.16–5.7 years). 
At primary infection of the 102 seroconverters, 53 also 
showed other markers of HBoV1 infection (Table 2): 
viremia in 24, IgM antibodies in 28, and low avidity of IgG 
in 34. In subsequent follow-up, IgG avidity matured in all 
but 2 children.
Only 2 children showed IgM antibodies in 2 
consecutive samples, with intervals of 83 and 174 days. 
The corresponding intervals for the other children were 74–
311 days, median 164. Only 4 children showed transient 
low-level IgM antibody reactivity (mean absorbance 0.335, 
median 0.285) in 1 serum sample long after seroconversion. 
One of these 4 IgM-ambiguous samples also was falsely 
IgM antibody positive for B19 parvovirus, which suggested 
nonspeciﬁ   city. None of them contained HBoV1 DNA, 
but all contained high-avidity HBoV1 IgG antibodies, 
indicating preexisting immunity.
In 73 (67%) of the 109 children, IgG antibody levels 
after seroconversion remained stable or decreased only 
slightly during follow-up (Tables 1, 3; Figure 2). They 
decreased substantially over time in 26 (24%) children, 
10 of whom turned seronegative during follow-up. In 
all, 38 (35%) children had >1 (44 in total) diagnostic 
secondary HBoV1 immunoactivations (>4-fold increase 
in IgG antibody titer in 2 consecutive samples; Figure 1), 
including 7 reconversions (Figure 2). None of the 44 serum 
pairs showing secondary responses contained HBoV1 
DNA or IgM antibodies (the latter with 1 exception; the 
nonspeciﬁ  c B19 IgM-reactive serum), and 42 contained 
IgG of high avidity. In addition, some of the children 
showed nondiagnostic ﬂ   uctuations in the IgG antibody 
level.
All 7 children who lacked a primary seroconversion 
had been IgG positive from birth (Figure 2). Their umbilical 
cord samples showed high IgG avidity and lacked IgM and 
viral DNA. During follow-up, each of these 7 children 
experienced >1 (2 children had 3) secondary IgG increases 
within their ﬁ  rst 5 years of life.
For 88 children, the ﬁ  rst samples were taken during 
the ﬁ  rst 6 months (median 3.7 months of life); 35 (40%) 
had maternal IgG antibodies (Table 1). One child in this 
age group showed an HBoV1 primary infection (at 3.7 
months): presence of IgM antibodies, IgG conversion, and 
viremia. An episode of AOM preceded the viremic sample. 
Another child had a borderline IgM antibody result in her 
ﬁ  rst available sample but exhibited waning (maternal) IgG 
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Figure 1. Age distribution of 
children with primary and 
secondary human bocavirus 
(HBoV) immune responses 
and seroprevalence of 
HBoV1 IgG, Finland.Association of HBoV1 Infection with Respiratory Disease
antibodies. However, umbilical cord blood samples from 
both of these children were negative for IgM antibodies 
and DNA, and IgG antibodies were of high avidity, ruling 
against congenital infection.
Real-time qPCR
At primary infection, viral DNA was detectable in the 
serum of 24 of the 102 children with a mean of 1.21 × 105 
copies/mL (Table 2). However, none of the serum samples 
with secondary immune responses was PCR positive. 
No child had HBoV1 DNA in 2 consecutive samples 
(postviremic sampling interval 74–207 days, mean 128 
days, median 96 days).
Clinical Correlates
Infection-related symptoms were reported in 90% 
of the children during the HBoV1 primary infection and 
in 70% during the subsequent sampling interval (Table 
4) (p = 0.0003). When comparing individual symptoms, 
2 conditions, URTI (60%) and AOM (47%), occurred 
signiﬁ  cantly more frequently during the HBoV1 primary 
infection than during the subsequent interval (36% and 
31%; p = 0.0002 and p = 0.026). LRTI was also more 
frequent during the HBoV1 primary infection (5%) 
than during the next interval (0%) but was too rare for 
the difference to reach signiﬁ   cance; however, when 
combined with URTI, the difference was highly signiﬁ  cant 
(p<0.0001). The secondary immune responses, including 
reconversions, showed no association with symptoms 
(Table 4). The results were similar, regardless of whether 
the symptoms of HBoV1 infection were compared with 
those of the previous or the subsequent interval (Table 4). 
Neither the previous nor the subsequent sampling interval 
differed signiﬁ   cantly in length from the seroconversion 
interval. The mean differences in length compared with the 
seroconversion interval were the following: –16.6 days for 
the previous and +0.5 days for the subsequent interval. 
Stability and decline in HBoV1 IgG absorbance level 
in long-term follow-up were not associated either with 
diabetes-related autoantibody positivity, allergic disease, 
or symptoms during HBoV1 primary infection. They were 
also not associated with excess susceptibility to infections 
in general.
Discussion
By comprehensive serologic and molecular testing 
and follow-up, we observed that by 6 years of age, all 
children were infected with HBoV1. Reports state that 
HBoV1 infects predominantly children, and at a young age 
(2,3), but almost all studies have been symptom and PCR 
based and cross-sectional, whereas our study was serum 
based and longitudinal and spanned the entire period from 
infancy through 13 years of age.
 We determined the seroepidemiology and clinical 
correlates of HBoV1 infections and the kinetics of HBoV1 
infection markers in sequential serum samples from 
constitutionally healthy children. We showed that HBoV1 
primary infections, but not secondary immunoactivations, 
were signiﬁ  cantly associated with respiratory illness and 
with AOM.
A deﬁ  nitive IgG seroconversion was evident in 102 of 
the 109 children, half of whom showed further markers of 
HBoV1 primary infection: viremia, IgM antibodies, or low 
avidity of IgG. The frequency of viremia or IgM antibody 
positivity in children with HBoV1 primary infection was 
considerably lower here than in our earlier study in which 
45 of 48 wheezing children with serologically veriﬁ  ed 
HBoV1 primary infection were viremic, and all but 1 who 
seroconverted had IgM antibodies (13). Unlike our current 
population-based study, our earlier study comprised 
symptomatic children who gave samples at short intervals 
during their acute disease. Our PCR results are concordant 
with the earlier results that showed the brevity of HBoV1 
viremia. IgM antibodies persisted slightly longer than 
did the viremia and were detectable in one fourth of the 
ﬁ  rst IgG-positive serum samples. For human parvovirus 
B19 (B19V), another pathogenic human parvovirus, the 
kinetics are the reverse, with viremia usually outlasting 
IgM antibodies and persisting at a low level for months or 
years (22). In longevity of diagnostic ﬁ  ndings, the 3 assays 
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Table 1. Human bocavirus IgG results from 109 constitutionally 
healthy children, Finland 
Result* No.  (%) 
Age, y 
Mean Median  Range 
Seroconversion 102  (94)  2.30 2.08  0.31–6.00 
Secondary 
response†
38 (35)  4.79  4.77  0.73–9.79 
Reconversion 7  (6)  6.29  7.07  1.59–8.15 
*Maternal antibodies, i.e., low-level (vanishing) IgG, were detected in 
35/88 children from whom serum was taken d6 mo. of age. Seven children 
were IgG positive from birth, and their maternal antibodies were not seen 
to disappear before induction of their own immunity. For 73, the IgG level 
remained high; for 26, the IgG level decreased with time; and 10 
underwent IgG reversion. 
†>4-fold increase in, or reconversion of, high avidity IgG (2 children had 2 
and 2 other children had 3 secondary immune responses).  
Table 2. Human bocavirus 1 findings of 102 constitutionally healthy children at seroconversion, Finland* 
No. (%) children  Virologic finding  Mean  Median Range 
28 (27)  IgM antibodies, abs  0.69 0.66 0.17–1.54 
24 (24)  qPCR positive, copies/mL  1.21 × 10
5 4.13 × 10
4 1.26 × 10
0 to –9.09 × 10
5
34 (33)  Low IgG avidity, %  8.6 9.4 1.5–14.4 
*Abs, absorbance value; qPCR, quantitative PCR in serum. RESEARCH
for HBoV1 ranked in this order: IgG-avidity EIA, IgM 
EIA, serum PCR.
Regarding the high HBoV1 IgG antibody 
seroprevalence, which has exceeded 90% in adults (13,23–
26), we recently observed HBoV1 IgG secondary responses 
in a large proportion of immunocompetent adults (17). In 
the current study, two thirds of children maintained steady 
IgG antibody levels for years after seroconversion. In one 
fourth, however, antibody levels declined substantially 
with time, and in some cases fell below the detection 
limit. In most of the children with such a reversion, the 
HBoV1 IgG antibodies later reconverted. Altogether, 38 
(35%) children exhibited diagnostic secondary HBoV1 
IgG antibody responses: in 2 children 2× and in another 
2 children 3×. The secondary immunoactivations were 
generally of high avidity and lacked IgM antibodies and 
were always nonviremic. If these events represent HBoV1 
secondary infections, they must be local rather than 
systemic infections, or they produce short-lived or low-
titer viremia that escaped PCR detection. That they were 
nonviremic would agree with the possibility of B cell 
boosting by related viruses. The most plausible candidates 
for such closely related immunogens are the recently 
discovered HBoV species HBoV2–4 (4–6), or even more 
intriguingly, some currently unknown viruses. Past-
immunity IgG antibodies against HBoV1–4 cross-react; 
however, both IgM and IgG antibodies of the acute phase 
are HBoV1 speciﬁ  c (27).
Seven children remained HBoV IgG antibody positive 
from birth through follow-up, without any observable 
seroconversion or other acute HBoV-infection markers. 
The absence of HBoV IgM antibodies and DNA from their 
umbilical cord blood samples argues against congenital 
infection. This is in line with a recently noted absence of 
HBoV from amniotic ﬂ  uid or fetal tissues (28,29). The 
lengths of the sampling intervals may have concealed the 
disappearance of maternal antibodies and the appearance 
of markers for HBoV acute infection in the infant. 
Alternatively, instead of a full replicative infection, the 
virus could induce a vaccination-like immunity because of 
preexisting maternal antibodies. Within the ﬁ  rst months of 
life, maternal HBoV IgG antibodies have been observable 
at prevalences of 26%–78%, depending on the child’s 
age (13,23,24,30), similar to the 40% at a mean age of 4 
months in our study. Because only 1 child had detectable 
HBoV primary infection during the ﬁ  rst 6 months of life, 
the maternal antibodies as a rule seem to be protective—or 
the infants were less exposed.
The  ﬁ   rst HBoV prevalence studies showed low 
detection frequencies of HBoV DNA in the respiratory 
tracts of asymptomatic children and a high co-infection 
rate (31–33). However, subsequent studies indicated a 
prolonged and frequent presence of HBoV DNA also in 
asymptomatic children (7–11). Because of these features 
and the frequent co-detection of other viruses, the role of 
HBoV as a respiratory pathogen has been questioned. In 
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1 0.33 120 0.061  Neg  0.015  Neg 
2 0.99 235 0.010  Neg  0.014  Neg 
3 1.25 96 0.029  Neg  0.025  Neg 
4 1.52 96 0.032  Neg  0.023  Neg 
5 1.77 90 0.032  Neg  0.021  Neg 
6 2.02 89 0.017  Neg  0.022  Neg 
7 2.52 180 0.019  Neg  0.028  Neg 
8 2.97 165 0.014  Neg  0.028  Neg  Neg  Neg 
9 3.44 167 1.536  Pos  0.730  Pos  2.8 7.67 × 10
4
10 3.93 178 2.883  Pos 0.023  Neg  60.8 Neg 
11 4.46 190 3.412  Pos 0.035  Neg 
12 4.91 163 3.111  Pos 0.022  Neg 
13 5.45 193 3.754  Pos 0.033  Neg 
14 5.96 185 3.228  Pos 0.020  Neg 
15 7.07 398 3.183  Pos 0.030  Neg 
16 7.52 163 3.102  Pos 0.026  Neg 
17 8.07 198 3.450  Pos 0.027  Neg 
18 8.53 165 3.149  Pos 0.016  Neg 
19 9.07 195 3.252  Pos 0.024  Neg  49.2
*This child experienced an acute HBoV infection at 3 years of age (sample no. 9), evidenced by: IgG conversion, IgM, low IgG avidity and viremia 
(boldface). HBoV, human bocavirus; qPCR, quantitative PCR in serum; neg, negative; pos, positive; blank cells, not done. 
†The cutoff absorbances for negative and positive IgG results were 0.154 (mean + 3 SD) and 0.188 (mean + 4 SD), respectively (13).
‡The cutoff absorbances for negative and positive IgM results were 0.136 (mean + 3 SD) and 0.167 (mean + 4 SD), respectively (13).
§The low- and high-avidity cutoff values: 15% and 25%, respectively (17).Association of HBoV1 Infection with Respiratory Disease
a recent prospective study of children in day care, neither 
HBoV DNA presence nor its load in nasal swabs was 
associated with the presence or severity of respiratory illness 
(11). On the other hand, low-load HBoV PCR positivity in 
the upper respiratory tract does not reliably indicate acute 
HBoV infection, and therefore an accurate diagnosis of 
acute HBoV infection requires a serum specimen (12–16).
We collected consecutive serum samples from 
constitutionally healthy children and recorded the appearance 
of HBoV antibodies. The parents were interviewed during 
each sample-collection visit about the child’s symptoms 
within that interval. We compared symptoms during the 
seroconversion interval with those during the subsequent 
interval for each child, and, taking into account the slight 
age difference and variations in occurrences of other 
respiratory viruses, also to symptoms during the previous 
sampling interval. With both approaches, HBoV primary 
infection was unambiguously associated with URTI and 
with combined URTI and LRTI, strongly suggesting that 
HBoV does cause respiratory illness. Furthermore, our 
result linking AOM with HBoV primary infection, in 
concert with 2 previous studies’ detection of HBoV DNA 
in middle ear ﬂ  uid (34,35), indicates a close association for 
HBoV also with AOM and middle ear effusion. That these 
children were genetically susceptible to type 1 diabetes (18) 
most likely does not affect this interpretation of our data.
Even though the strength of our study is the close 
monitoring of children over a long period (1996–2006), the 
sampling intervals were too long for any detailed analysis 
of the seasonal distribution of the infections. However, 
even distribution throughout the year was evident, which 
reduced the possibility that HBoV1 infections would 
accumulate within peak season(s) of other particularly 
pathogenic viruses, which, at least in theory, could have 
resulted in a false disease association. Although we did 
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Figure 2. IgG responses in follow-up serum samples from 5 
representative children in a study of human bocavirus 1 infection, 
Finland.
Table 4. Infection-related signs and symptoms during human bocavirus 1 primary seroconversions and secondary responses 
compared with the previous and subsequent sampling interval, Finland* 
Sign or 
symptom 
Primary immune response, n = 101  Secondary immune response, n = 43 
Interval,†
no. (%) 
Previous interval‡  Next interval§  Interval,¶
no. (%) 
Previous interval#  Next interval** 
No. (%)  p value  No. (%)  p value  No. (%)  p value  No. (%)  p value
URTI  61 (60.4)  34 (33.7)  0.0002   36  (35.6) 0.0002  24 (55.8)  21 (48.8)  0.53    23 (53.5) 1 
LRTI  5 (4.9)  2 (2.0)  0.45    0  –  1 (2.3)  3 (7.0)  0.62    2 (4.6)  1 
URTI or LRTI  62 (61.4)  36 (35.6)  0.0003   36  (35.6) <0.0001 24 (55.8)  22 (51.2)  0.83    23 (53.5) 1 
Fever without 
RTI 
14 (13.9)  9 (8.9)  0.30    10 (9.9)  0.54  7 (16.3)  3 (7.0)  0.22    3 (7.0)  0.34 
Acute otitis 
media
47 (46.5)  33 (32.7)  0.024   31  (30.7) 0.026  12 (27.9)  8 (18.6)  0.45    5 (11.6)  0.06 
Acute tonsillitis  0  1 (1.0)  –    1 (1.0)  –  1 (2.3)  1 (2.3)  1    0  – 
Acute
conjunctivitis 
5 (4.9)  3 (3.0)  0.72    8 (7.9)  0.51  1 (2.3)  5 (11.6)  0.12    2 (4.6)  1 
Acute sinusitis  2 (2.0)  0  –    1 (1.0)  1  2 (4.6)  3 (7.0)  1    2 (4.6)  – 
Gastroenteritis  23 (22.8)  19 (18.8)  0.62    16 (15.8) 0.30  9 (20.9)  8 (18.6)  1    10 (23.3) 1 
Exanthema, 
fever
8 (7.9)  4 (4.0)  0.34    0  –  0  1 (2.3)  –    0  – 
Other  8 (7.9)  3 (3.0)  0.23    6 (5.9)  0.79  4 (9.3)  2 (4.6)  0.62    3 (7.0)  1 
Totals  91 (90.1)  74 (73.3)  0.003   71  (70.3) 0.0003  35 (81.4)  30 (69.8)  0.27    32 (74.4) 0.58 
*URTI, upper respiratory tract illness; LRTI, lower respiratory tract illness; RTI, respiratory tract infection; –, could not be calculated. Boldface indicates 
statistical significance by Liddell exact test (<0.05). 
†Length of intervals, d: mean 155, median 166, range 75–361; mean age 2.3 y, median age 2.1 y. 
‡Length of intervals, d: mean 139, median 130, range 73–358. 
§Length of intervals, d: mean 155, median 169, range 61–615. 
¶Length of intervals, d: mean 188, median 176, range 78–537, mean age 4.8 y, median 4.8 y. 
#Length of intervals, d: mean 181, median 182, range 61–415. 
**Length of intervals, d: mean 183, median 176, range 88–408. One child was omitted because of lack of clinical information for 1 interval. RESEARCH
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not screen for other respiratory pathogens, the scheduled 
sampling according to the ages of the children instead of 
seasons further reduced the possibility of seasonal bias.
In our longitudinal study, all children acquired HBoV 
infection by 6 years of age. Although most of them 
subsequently maintained stable HBoV IgG antibody levels, 
in one fourth, levels substantially declined, and some 
children lost their antibodies completely, with subsequent 
reconversion. Secondary infections or anamnestic immune 
responses commonly occurred. Among the children with 
HBoV primary infection, >60% had respiratory symptoms. 
Whereas HBoV primary infections were strongly associated 
with respiratory illness, the secondary immunoactivations 
were not. Our results indicate that HBoV1 is a true and 
common respiratory pathogen.
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